Drug-drug interactions between COVID-19 drug therapies and antidepressants

References

• Roehrig C. Mental disorders top the list of the most costly conditions in the United States roehrig C mental disorders top the list of the most costly conditions in the United States: $201 billion. Health Aff. 2016 Jun 1;35(6):1130–1135. doi:10.1377/hlthaff.2015.1659
   PubMed Web of Science ®Google Scholar
• Theis KA, Roblin DW, Helmick CG, et al. Prevalence and causes of work disability among working-age U.S. adults, 2011-2013, NHIS. Disabil Health J. 2018 Jan;11(1):108–115. doi: 10.1016/j.dhjo.2017.04.010
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Sep;21(9):655–679. doi: 10.1016/j.euroneuro.2011.07.018
   PubMed Web of Science ®Google Scholar
• Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg. 2020 Jun;78:185–193.
   PubMed Web of Science ®Google Scholar
• Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020 Apr;76:71–76.
   PubMed Web of Science ®Google Scholar
• Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012 Jan;11(1):83–94. doi: 10.1517/14740338.2012.631910
   PubMed Web of Science ®Google Scholar
• Hutson S. Researchers sound alarm on ‘silent’ drug interactions. Nat Med. 2011 Jan;17(1):6. doi: 10.1038/nm0111-6
   PubMed Web of Science ®Google Scholar
• Manjhi PK, Kumar R, Priya A, et al. Drug-drug interactions in patients with COVID-19: a retrospective study at a tertiary care hospital in Eastern India. Maedica (Bucur). 2021 Jun;16(2):163–169. doi: 10.26574/maedica.2021.16.2.163
   PubMedGoogle Scholar
• Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017;4(5):409–418. doi: 10.1016/S2215-0366(17)30015-9
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61 Suppl 6(6):4–6.
   PubMedGoogle Scholar
• Wong DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995;57(5):411–441. doi: 10.1016/0024-3205(95)00209-O
   PubMed Web of Science ®Google Scholar
• Kokras N, Dalla C. Sex differences in animal models of psychiatric disorders. Br J Pharmacol. 2014 Oct;171(20):4595–619. doi: 10.1111/bph.12710
   PubMed Web of Science ®Google Scholar
• Kokras N, Dalla C. Preclinical sex differences in depression and antidepressant response: Implications for clinical research. J Neurosci Res. 2017 Jan 2;95(1–2):731–736. doi: 10.1002/jnr.23861
   PubMed Web of Science ®Google Scholar
• Kokras N, Dalla C, Papadopoulou-Daifoti Z. Sex differences in pharmacokinetics of antidepressants. Expert opinion on drug metabolism & toxicology. Expert Opin Drug Metab Toxicol. 2011;7(2):213–226. doi: 10.1517/17425255.2011.544250
   PubMed Web of Science ®Google Scholar
• Ables AZ, BAUGHMAN IO. Antidepressants: update on new agents and indications. Am Fam Physician. 2003;67(3):547–555.
   PubMed Web of Science ®Google Scholar
• Zohar J, Stahl S, Moller H-J, et al. A review of the current nomenclature for psychotropic agents and an introduction to the neuroscience-based nomenclature. Eur Neuropsychopharmacol. 2015;25(12):2318–2325.
   PubMed Web of Science ®Google Scholar
• Miguel C, Albuquerque E. Drug interaction in psycho-oncology: antidepressants and antineoplastics. Pharmacology. 2011;88(5–6):333–339. doi: 10.1159/000334738
   PubMed Web of Science ®Google Scholar
• Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc. 1997 Sep;72(9):835–847. doi: 10.4065/72.9.835
   PubMed Web of Science ®Google Scholar
• Spina E, Barbieri MA, Cicala G, et al. Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. Expert Opin Drug Metab Toxicol. 2020;16(1):31–44.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153(3):311–320.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Von Moltke LL, Harmatz JS, et al. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry. 1998;59(15):19–27. doi: 10.1097/00004714-199910001-00003
   PubMedGoogle Scholar
• Zemanova N, Anzenbacher P, Anzenbacherova E. The role of cytochromes P450 in the metabolism of selected antidepressants and anxiolytics under psychological stress. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022;166(2):140–149. doi: 10.5507/bp.2022.019
   PubMed Web of Science ®Google Scholar
• Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics. 2005 Sep;46(5):464–494. doi: 10.1176/appi.psy.46.5.464
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Lynch JB, Del Rio C, et al. Mild or moderate covid-19. N Engl J Med. 2020 Oct 29;383(18):1757–1766. doi: 10.1056/NEJMcp2009249
   PubMed Web of Science ®Google Scholar
• Lui G, Guaraldi G. Drug treatment of COVID-19 infection. Curr Opin Pulm Med. 2023 May 1;29(3):174–183. doi: 10.1097/MCP.0000000000000953
   PubMed Web of Science ®Google Scholar
• AC–TfIwC-S G, Ginde AA, Paredes R. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022 Oct;10(10):972–984. doi: 10.1016/S2213-2600(22)00215-6
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of Sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022 Apr 5;327(13):1236–1246. doi: 10.1001/jama.2022.2832
   PubMed Web of Science ®Google Scholar
• Stasi C, Fallani S, Voller F, et al. Treatment for COVID-19: an overview. Eur J Pharmacol. 2020 Dec 15;889:173644. doi: 10.1016/j.ejphar.2020.173644
   PubMed Web of Science ®Google Scholar
• COVID-19 Treatment Guidelines. [Internet]. Bethesda (MD): National Institutes of Health (NIH). [cited 2023 Jul 7]. Available from: https://www.covid19treatmentguidelines.nih.gov/.
   Google Scholar
• Anakirna emergency use authorization. [Internet]. (MD) United States: FDA [cited 2023 Jul 8]. Available from: https://www.fda.gov/media/163081/download.
   Google Scholar
• Levy G, Guglielmelli P, Langmuir P, et al. JAK inhibitors and COVID-19. J Immunother Cancer. 2022 Apr;10(4):e002838. doi: 10.1136/jitc-2021-002838
   PubMed Web of Science ®Google Scholar
• Kmietowicz Z. Covid-19: WHO recommends baricitinib and sotrovimab to treat patients. BMJ. 2022 Jan 13;376:o97. doi: 10.1136/bmj.o97
   PubMedGoogle Scholar
• Reddy Vegivinti CT, Pederson JM, Saravu K, et al. Remdesivir therapy in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Ann Med Surg. 2021 Feb;62:43–48.
   PubMed Web of Science ®Google Scholar
• Vlaar APJ, Witzenrath M, van Paassen P, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022 Dec;10(12):1137–1146. doi: 10.1016/S2213-2600(22)00297-1
   PubMed Web of Science ®Google Scholar
• Ma H, O’Kennedy R. The structure of natural and recombinant antibodies. Methods Mol Biol. 2015;1348:7–11.
   PubMedGoogle Scholar
• Wootla B, Denic A, Rodriguez M. Polyclonal and monoclonal antibodies in clinic. Methods Mol Biol. 2014;1060:79–110.
   PubMedGoogle Scholar
• Nelson PN, Reynolds GM, Waldron EE, et al. Monoclonal antibodies. Mol Pathol. 2000 Jun;53(3):111–117. doi: 10.1136/mp.53.3.111
   PubMedGoogle Scholar
• Shepard HM, Phillips GL, DT C, et al. Developments in therapy with monoclonal antibodies and related proteins. Clin Med. 2017 Jun;17(3):220–232. doi: 10.7861/clinmedicine.17-3-220
   PubMed Web of Science ®Google Scholar
• Lloyd EC, Gandhi TN, Petty LA. Monoclonal antibodies for COVID-19. JAMA. 2021 Mar 9;325(10):1015. doi: 10.1001/jama.2021.1225
   PubMedGoogle Scholar
• Hwang YC, Lu RM, Su SC, et al. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci. 2022 Jan 4;29(1):1. doi: 10.1186/s12929-021-00784-w
   PubMed Web of Science ®Google Scholar
• Chavda VP, Prajapati R, Lathigara D, et al. Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opin Biol Ther. 2022 Jun;22(6):763–780. doi: 10.1080/14712598.2022.2078160
   PubMed Web of Science ®Google Scholar
• Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016 Mar 17;531(7594):381–385. doi: 10.1038/nature17180
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - final report. N Engl J Med. 2020 Nov 5;383(19):1813–1826. doi: 10.1056/NEJMoa2007764
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med. 2022 Jan 27;386(4):305–315. doi: 10.1056/NEJMoa2116846
   PubMed Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020 May 15;295(20):6785–6797. doi: 10.1074/jbc.RA120.013679
   PubMed Web of Science ®Google Scholar
• Deb S, Reeves AA, Hopefl R, et al. ADME and pharmacokinetic properties of Remdesivir: its drug interaction potential. Pharmaceuticals (Basel). 2021 Jul 8;14(7):655. doi: 10.3390/ph14070655
   PubMedGoogle Scholar
• Yang K. What do we know about remdesivir drug interactions? Clin Transl Sci. 2020 Sep;13(5):842–844. doi: 10.1111/cts.12815
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Remdesivir 2023. Available from: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/remdesivir
   Google Scholar
• European Medicines Agency. Summary on compassionate use: remdesivir 2020. Available from: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf
   Google Scholar
• Bahcecioglu OF, Gok S, Durmus M. Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor? Eur J Hosp Pharm. 2021 Mar;28(2):e6. doi: 10.1136/ejhpharm-2021-002680
   PubMedGoogle Scholar
• Indari O, Jakhmola S, Manivannan E, et al. An update on antiviral therapy against SARS-CoV-2: how far have we come? Front Pharmacol. 2021;12:632677. doi: 10.3389/fphar.2021.632677
   PubMed Web of Science ®Google Scholar
• van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29(1):1–9. doi: 10.2165/00003088-199500291-00003
   PubMedGoogle Scholar
• Brunotte L, Zheng S, Mecate-Zambrano A, et al. Combination therapy with fluoxetine and the nucleoside analog gs-441524 exerts synergistic antiviral effects against different SARS-CoV-2 variants in vitro. Pharmaceutics. 2021 Sep 3;13(9):1400. doi: 10.3390/pharmaceutics13091400
   PubMed Web of Science ®Google Scholar
• Schloer S, Brunotte L, Mecate-Zambrano A, et al. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. Br J Pharmacol. 2021 Jun;178(11):2339–2350. doi: 10.1111/bph.15418
   PubMed Web of Science ®Google Scholar
• Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008 May;9(4):310–322. doi: 10.2174/138920008784220664
   PubMed Web of Science ®Google Scholar
• Landerholm A, Fedotova NO, Levy-Carrick NC, et al. C-L case conference: torsades de pointes in a patient with lifelong Medical trauma, COVID-19, remdesivir, citalopram, quetiapine, and Hemodialysis. J Acad Consult Liaison Psychiatry. 2023 Mar;64(2):147–157. doi: 10.1016/j.jaclp.2022.11.001
   PubMedGoogle Scholar
• de Gage S B, Collin C, Le-Tri T, et al. Antidepressants and Hepatotoxicity: a cohort study among 5 million individuals registered in the French National Health Insurance database. CNS Drugs. 2018 Jul;32(7):673–684. doi: 10.1007/s40263-018-0537-1
   PubMed Web of Science ®Google Scholar
• Hampton T. New flu antiviral Candidate May thwart drug resistance. JAMA. 2020 Jan 7;323(1):17. doi: 10.1001/jama.2019.20225
   PubMed Web of Science ®Google Scholar
• EUA for Lagevrio. [Internet]. (MD) United States: FDA [cited 2023 Jul 7]. Available from: https://www.fda.gov/media/155054/download.
   Google Scholar
• European Medicines Agency. Lagevrio: withdrawal of the marketing authorisation application 2023. Available from: https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/lagevrio
   Google Scholar
• Atmar RL, Finch N. New perspectives on antimicrobial agents: molnupiravir and Nirmatrelvir/ritonavir for treatment of COVID-19. Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0240421. doi: 10.1128/aac.02404-21
   PubMed Web of Science ®Google Scholar
• Molnupiravir and NHC as perpetrators. [Internet]. Amsterdam: European Medicines Agency (EMA), [cited 2023 Jul 7]. Available from: https://www.ema.europa.eu/en/documents/referral/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-assessment-report_en.pdf.
   Google Scholar
• Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023 Feb 8;76(3):e342–e349. doi: 10.1093/cid/ciac443
   PubMed Web of Science ®Google Scholar
• Cai H, Yan J, Liu S, et al. Paxlovid for hospitalized COVID-19 patients with chronic kidney disease. Antiviral Res. 2023 Jun 25;216:105659. doi: 10.1016/j.antiviral.2023.105659
   PubMed Web of Science ®Google Scholar
• EUA for Paxlovid. [Internet]. (MD) United States: FDA [cited 2023 Jul 7]. Available from: https://www.fda.gov/media/155049/download.
   Google Scholar
• Blair HA. Nirmatrelvir plus ritonavir in COVID-19: a profile of its use. Drugs Ther Perspect. 2023;39(2):41–47. doi: 10.1007/s40267-022-00971-1
   PubMedGoogle Scholar
• Kane AM, Keenan EM, Lee K, et al. Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: a retrospective observational study. J Am Coll Clin Pharm. 2023 Jan;6(1):29–33. doi: 10.1002/jac5.1729
   PubMedGoogle Scholar
• Azanza JR, Mensa J, Gonzalez Del Castillo J, et al. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences. Rev Esp Quimioter. 2022 Aug;35(4):357–361. doi: 10.37201/req/054.2022
   PubMed Web of Science ®Google Scholar
• Penzak SR, Hon YY, Lawhorn WD, et al. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol. 2002 Aug;22(4):366–370. doi: 10.1097/00004714-200208000-00006
   PubMed Web of Science ®Google Scholar
• VandenBrink BM, Foti RS, Rock DA, et al. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos. 2012 Jan;40(1):47–53. doi: 10.1124/dmd.111.041210
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005 May 26;352(21):2211–21. doi: 10.1056/NEJMra032424
   PubMed Web of Science ®Google Scholar
• Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995 Jun;29(6):619–624. doi: 10.1177/106002809502900612
   PubMed Web of Science ®Google Scholar
• Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000 Apr;20(2):246–251. doi: 10.1097/00004714-200004000-00019
   PubMed Web of Science ®Google Scholar
• Loos NHC, Beijnen JH, Schinkel AH. The mechanism-based inactivation of CYP3A4 by Ritonavir: what mechanism? Int J Mol Sci. 2022 Aug 30;23(17):9866. doi: 10.3390/ijms23179866
   PubMed Web of Science ®Google Scholar
• IL K, Calmy A, Ambrosioni J, et al. Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient. AIDS. 2012 Nov 28;26(18):2417–2418. doi: 10.1097/QAD.0b013e32835a11ba
   PubMed Web of Science ®Google Scholar
• Group RC, Abbas A, Abbas F. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022 Jul 30;400(10349):359–368. doi: 10.1016/S0140-6736(22)01109-6
   PubMed Web of Science ®Google Scholar
• Baricitinib EUA Letter of authorization. [Internet]. (MD) United States: FDA [cited 2023 Jul 7]. Available from: https://www.fda.gov/media/143822/download.
   Google Scholar
• Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021 Mar;591(7848):92–98. doi: 10.1038/s41586-020-03065-y
   PubMed Web of Science ®Google Scholar
• Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30–e31. doi: 10.1016/S0140-6736(20)30304-4
   PubMed Web of Science ®Google Scholar
• Assadiasl S, Fatahi Y, Mosharmovahed B, et al. Baricitinib: From Rheumatoid Arthritis to COVID-19. J Clin Pharmacol. 2021 Oct;61(10):1274–1285. doi: 10.1002/jcph.1874
   PubMed Web of Science ®Google Scholar
• Singh RK, Shi J, Zemaitaitis BW, et al. Olanzapine increases RGS7 protein expression via stimulation of the janus tyrosine kinase-signal transducer and activator of transcription signaling cascade. J Pharmacol Exp Ther. 2007 Jul;322(1):133–140. doi: 10.1124/jpet.107.120386
   PubMed Web of Science ®Google Scholar
• Fernandez-Clotet A, Castro-Poceiro J, Panes J. Tofacitinib for the treatment of ulcerative colitis. Expert Rev Clin Immunol. 2018 Nov;14(11):881–892. doi: 10.1080/1744666X.2018.1532291
   PubMed Web of Science ®Google Scholar
• Berekmeri A, Mahmood F, Wittmann M, et al. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018 Sep;14(9):719–730. doi: 10.1080/1744666X.2018.1512404
   PubMed Web of Science ®Google Scholar
• Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs. 2017 Dec;77(18):1987–2001. doi: 10.1007/s40265-017-0835-9
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234–4243. doi: 10.4049/jimmunol.1003668
   PubMed Web of Science ®Google Scholar
• Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014 Apr;42(4):759–773. doi: 10.1124/dmd.113.054940
   PubMed Web of Science ®Google Scholar
• Ye Z, Hu J, Wang J, et al. The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism. Chem Biol Interact. 2023 Apr 1;374:110398. doi: 10.1016/j.cbi.2023.110398
   PubMed Web of Science ®Google Scholar
• Walton A, Paik J, Quebe A, et al. Frequency of prescription claims for drugs that May interact with janus kinase inhibitors among patients with rheumatoid arthritis in the US. Rheumatol Ther. 2021 Mar;8(1):599–607. doi: 10.1007/s40744-020-00275-8
   PubMed Web of Science ®Google Scholar
• Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with still’s disease. Rheumatology (Oxford). 2019 Nov 1;58(Suppl 6):vi9–vi22. doi: 10.1093/rheumatology/kez350
   PubMedGoogle Scholar
• Dahms K, Mikolajewska A, Ansems K, et al. Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis. Eur J Med Res. 2023 Feb 25;28(1):100. doi: 10.1186/s40001-023-01072-z
   PubMed Web of Science ®Google Scholar
• Yang BB, Gozzi P, Sullivan JT. Pharmacokinetics of anakinra in subjects of heavier vs. Lighter body weights. Clin Transl Sci. 2019 Jul;12(4):371–378. doi: 10.1111/cts.12622
   PubMed Web of Science ®Google Scholar
• Lemaitre F, Solas C, Gregoire M, et al. Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundam Clin Pharmacol. 2020 Oct;34(5):530–547. doi: 10.1111/fcp.12586
   PubMed Web of Science ®Google Scholar
• Cayot A, Laroche D, Disson-Dautriche A, et al. Cytochrome P450 interactions and clinical implication in rheumatology. Clin Rheumatol. 2014 Sep;33(9):1231–1238. doi: 10.1007/s10067-014-2710-3
   PubMed Web of Science ®Google Scholar
• Gupta A, Bagri NK, Tripathy SK, et al. Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis. Rheumatol Int. 2020 Jan;40(1):153–159. doi: 10.1007/s00296-019-04363-z
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017 Jul 27;377(4):317–328. doi: 10.1056/NEJMoa1613849
   PubMed Web of Science ®Google Scholar
• Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017 Nov;77(17):1865–1879. doi: 10.1007/s40265-017-0829-7
   PubMed Web of Science ®Google Scholar
• Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019 Aug;15(8):813–822. doi: 10.1080/1744666X.2019.1629904
   PubMed Web of Science ®Google Scholar
• WHOREAfC-TW G, Shankar-Hari M, Vale CL, et al. Association between administration of IL-6 Antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021 Aug 10;326(6):499–518. doi: 10.1001/jama.2021.11330
   PubMed Web of Science ®Google Scholar
• Abidi E, El Nekidy WS, Alefishat E, et al. Tocilizumab and COVID-19: timing of administration and efficacy. Front Pharmacol. 2022;13:825749. doi: 10.3389/fphar.2022.825749
   PubMed Web of Science ®Google Scholar
• Conti V, Corbi G, Sellitto C, et al. Effect of tocilizumab in reducing the mortality rate in COVID-19 patients: a systematic review with meta-analysis. J Pers Med. 2021 Jul 1;11(7):628. doi: 10.3390/jpm11070628
   PubMed Web of Science ®Google Scholar
• Investigators R-C, Gordon AC, Mouncey PR, et al. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N Engl J Med. 2021 Apr 22;384(16):1491–1502.
   PubMed Web of Science ®Google Scholar
• Gupta S, Wang W, Hayek SS, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021 Jan 1;181(1):41–51. doi: 10.1001/jamainternmed.2020.6252
   PubMed Web of Science ®Google Scholar
• Maraolo AE, Crispo A, Piezzo M, et al. The use of tocilizumab in patients with COVID-19: a systematic review, meta-analysis and trial sequential analysis of randomized controlled studies. J Clin Med. 2021 Oct 25;10(21):4935. doi: 10.3390/jcm10214935
   PubMed Web of Science ®Google Scholar
• Gatti M, Fusaroli M, Caraceni P, et al. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19. Br J Clin Pharmacol. 2021 Mar;87(3):1533–1540. doi: 10.1111/bcp.14459
   PubMed Web of Science ®Google Scholar
• Schmitt C, Kuhn B, Zhang X, et al. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011 May;89(5):735–740. doi: 10.1038/clpt.2011.35
   PubMed Web of Science ®Google Scholar
• Villemure S, Trenaman SC, Goralski KB. The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions. Expert Opin Drug Metab Toxicol. 2023 Jun 26;19(6):1–4. doi: 10.1080/17425255.2023.2228680
   PubMed Web of Science ®Google Scholar
• Pelechas E, Voulgari PV, Drosos AA. Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag. 2019;15:1073–1079. doi: 10.2147/TCRM.S167452
   PubMed Web of Science ®Google Scholar
• Livertox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Sarilumab. [Updated 2021 May 11]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547964/
   Google Scholar
• Khiali S, Rezagholizadeh A, Entezari-Maleki T. A comprehensive review on sarilumab in COVID-19. Expert Opin Biol Ther. 2021 May;21(5):615–626. doi: 10.1080/14712598.2021.1847269
   PubMed Web of Science ®Google Scholar
• Chamlagain R, Shah S, Sharma Paudel B, et al. Efficacy and safety of sarilumab in COVID-19: a systematic review. Interdiscip Perspect Infect Dis. 2021;2021:8903435. doi: 10.1155/2021/8903435
   PubMedGoogle Scholar
• Marino A, Munafo A, Augello E, et al. Sarilumab administration in COVID-19 patients: literature review and considerations. Infect Dis Rep. 2022 May 11;14(3):360–371. doi: 10.3390/idr14030040
   PubMed Web of Science ®Google Scholar
• Lee EB, Daskalakis N, Xu C, et al. Disease-drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacokinet. 2017 Jun;56(6):607–615. doi: 10.1007/s40262-016-0462-8
   PubMed Web of Science ®Google Scholar
• Syed YY. Regdanvimab: first approval. Drugs. 2021 Dec;81(18):2133–2137. doi: 10.1007/s40265-021-01626-7
   PubMed Web of Science ®Google Scholar
• Yang M, Li A, Jiang L, et al. Regdanvimab improves disease mortality and morbidity in patients with COVID-19: a meta-analysis. J Infect. 2022 Oct;85(4):e122–e124. doi: 10.1016/j.jinf.2022.05.044
   PubMed Web of Science ®Google Scholar
• Food and drug administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of Sotrovimab 2022. Available from: https://www.fda.gov/media/149534/download
   Google Scholar
• Heo Y-A. Sotrovimab: first approval. Drugs. 2022;82(4):477–484. doi: 10.1007/s40265-022-01690-7
   PubMed Web of Science ®Google Scholar
• Spanakis M, Ioannou P, Tzalis S, et al. Drug-drug interactions among patients hospitalized with COVID-19 in Greece. J Clin Med. 2022 Dec 2;11(23):7172. doi: 10.3390/jcm11237172
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FACT SHEET for HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION for EVUSHELDTM (tixagevimab co-packaged with cilgavimab) 2023. Available from: https://www.fda.gov/media/154701/download
   Google Scholar
• European Medicines Agency. Evusheld (tixagevimab/cilgavimab) 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/evusheld
   Google Scholar
• No Authors Listed Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19. JAMA. 2022 Jan 25 3274:384–385.10.1001/jama.2021.24931
   PubMed Web of Science ®Google Scholar
• Sherchan R, JP C. Casirivimab. StatPearls. Treasure Island (FL) 2023.
   Google Scholar
• Deeks ED. Casirivimab/Imdevimab: First Approval. Drugs. 2021 Nov;81(17):2047–2055. doi: 10.1007/s40265-021-01620-z
   PubMed Web of Science ®Google Scholar
• Gatti M, De Ponti F, Pea F. Clinically significant drug interactions between psychotropic agents and repurposed COVID-19 therapies. CNS Drugs. 2021 Apr;35(4):345–384. doi: 10.1007/s40263-021-00811-2
   PubMed Web of Science ®Google Scholar
• Vai B, Mazza MG, Marisa CD, et al. Joint European policy on the COVID-19 risks for people with mental disorders: an umbrella review and evidence-and consensus-based recommendations for mental and public health. Eur Psychiatry. 2022;65(1):e47.
   PubMed Web of Science ®Google Scholar
• Sarko J. Antidepressants, old and new. A review of their adverse effects and toxicity in overdose. Emerg Med Clin North Am. 2000 Nov;18(4):637–654. doi: 10.1016/S0733-8627(05)70151-6
   PubMed Web of Science ®Google Scholar
• de Leon J. Why do you keep telling me that drug-drug interactions are important in psychopharmacology when I do not see them in my clinical practice?: my failure to convince clinicians. J Clin Psychopharmacol. 2019;39(1):1–4. doi: 10.1097/JCP.0000000000000924
   PubMed Web of Science ®Google Scholar
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112–1120. doi: 10.1056/NEJMra041867
   PubMed Web of Science ®Google Scholar
• Beach SR, Celano CM, Noseworthy PA, et al. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1–13.
   PubMed Web of Science ®Google Scholar
• Ellahi R. Serotonin syndrome: a spectrum of toxicity. BJPsych Adv. 2015;21(5):324–332. doi: 10.1192/apt.bp.114.013037
   Google Scholar
• Uddin MF, Alweis, R, Shah, SR, et al. Controversies in Serotonin Syndrome Diagnosis and Management: A Review. J Clin Diagn Res. 2017 Sep;11(9):OE05–OE07. doi: 10.7860/JCDR/2017/29473.10696
   PubMedGoogle Scholar
• Juurlink D. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. BMJ. 2016;i5309. doi: 10.1136/bmj.i5309
   PubMedGoogle Scholar
• Crook H, Raza S, Nowell J, et al. Long covid—mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648
   PubMedGoogle Scholar
• Stauning MA, Gür DJ, Torp-Pedersen C, et al. COVID-19 mortality among selective serotonin reuptake inhibitor users—results from a nationwide cohort. Clin Microbiol Infect. 2023;29(8):1075–1082. doi: 10.1016/j.cmi.2023.04.028
   PubMed Web of Science ®Google Scholar
• Mahdi M, Herman L, Rethelyi JM, et al. Potential role of the antidepressants fluoxetine and fluvoxamine in the treatment of COVID-19. Int J Mol Sci. 2022 Mar 30;23(7):3812. doi: 10.3390/ijms23073812
   PubMed Web of Science ®Google Scholar
• Zheng W, Sun H-L, Cai H, et al. Antidepressants for COVID-19: a systematic review. J Affective Disorders. 2022;307:108–114. doi: 10.1016/j.jad.2022.03.059
   PubMed Web of Science ®Google Scholar
• Conti V, Sellitto C, Torsiello M, et al. Identification of drug interaction adverse events in patients with COVID-19: a systematic review. JAMA Netw Open. 2022 Apr 1;5(4):e227970. doi: 10.1001/jamanetworkopen.2022.7970
   PubMed Web of Science ®Google Scholar
• Borah P, Deb PK, Chandrasekaran B, et al. Neurological consequences of SARS-CoV-2 infection and concurrence of treatment-induced neuropsychiatric adverse events in COVID-19 patients: navigating the uncharted. Front Mol Biosci. 2021;8:627723. doi: 10.3389/fmolb.2021.627723
   PubMed Web of Science ®Google Scholar
• Plasencia-Garcia BO, Rodriguez-Menendez G, Rico-Rangel MI, et al. Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. Psychopharmacol (Berl). 2021 Feb;238(2):329–340. doi: 10.1007/s00213-020-05716-4
   PubMed Web of Science ®Google Scholar
• Marengoni A, Onder G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ. 2015;350(mar11 4):h1059–h1059. doi: 10.1136/bmj.h1059
   PubMedGoogle Scholar
• Dumbreck S, Flynn A, Nairn M, et al. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ. 2015;350(mar11 2):h949–h949.
   PubMed Web of Science ®Google Scholar
• Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–834.
   PubMed Web of Science ®Google Scholar
• Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12(4):407–422. doi: 10.1517/17425255.2016.1154043
   PubMed Web of Science ®Google Scholar
• Monteith S, Glenn T. Comparison of potential psychiatric drug interactions in six drug interaction database programs: a replication study after 2 years of updates. Hum Psychopharmacol Clin Exp. 2021;36(6):e2802. doi: 10.1002/hup.2802
   PubMed Web of Science ®Google Scholar